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P reeclampsia continues to be a major cause of maternal mortality, resulting in >50 000 maternal deaths worldwide each year, and is the leading cause of iatrogenic preterm birth. 1 To prevent preeclampsia, women at high risk of the condition need to be identifi ed early in pregnancy. Although there is signifi cant interest in the prediction of preeclampsia using combinations of clinical risk factors, biophysical measurements, and biochemical tests, to date no screening test has achieved the requisite sensitivity and specifi city to be useful and costeffective in a clinical setting. 2 -5 Prediction of preeclampsia in healthy nulliparous women is particularly challenging, despite the greatest proportion of cases occurring in this population. The best known combination of markers tested in a low-risk nulliparous population had a sensitivity of 46% for a specifi city of 80%, equating to a PPV of around 15.5%. 4 Other reports of better prediction have studied general obstetric populations that include high-risk women 3 or have used a nested case -control design with controls comprising uncomplicated pregnancies with the consequent overestimation of predictive performance. 6 A screening test is likely to require multiple biomarkers that refl ect different aspects of the complex pathological processes that culminate in preeclampsia. 7 Several proteins indicative of abnormal placentation, such as placental growth factor (PlGF) and pregnancy-associated plasma protein A, have been demonstrated to be predictive of preeclampsia, especially preterm disease. 8 Novel plasma biomarkers, representative of placentation or the maternal vascular and infl ammatory response in preeclampsia, may be discovered using an unbiased proteomic approach. Unfortunately, to date, most proteomic research, which has aimed to discover biomarkers, has failed to incorporate adequate biomarker validation studies in independent sample sets. These are necessary steps in the translation of potential biomarkers into reeclampsia continues to be a major cause of maternal mortality, resulting in >50 000 maternal deaths worldwide each year, and is the leading cause of iatrogenic preterm birth. 1 To prevent preeclampsia, women at high risk of the condition need to be identifi ed early in pregnancy. Although there is sigwomen 3 or have used a nested case -control design with conor have used a nested case -control design with conor trols comprising uncomplicated pregnancies with the consequent overestimation of predictive performance.
A screening test is likely to require multiple biomarkers that refl ect different aspects of the complex pathological and blood pressure. Predictive performances were maintained when exchanging mass spectrometry measurements with ELISA measurements for insulin-like growth factor acid labile subunit. In conclusion, we demonstrated that biomarker combinations centered on insulin-like growth factor acid labile subunit have the potential to predict preeclampsia in healthy nulliparous women. ( Hypertension ( Hypertension ( clinical practice. Recent development of sophisticated mass spectrometry -based quantitation of multiple proteins has enabled the validation of large sets of candidate biomarkers in plasma. 9 The objective of this study was to identify, verify, and validate panels of biomarkers, which are predictive of preeclampsia. Given that in current practice women with an estimated ≥ 20% risk of developing preeclampsia are referred for specialist prenatal care, 10 we aimed to develop a test with ≥ 50% sensitivity for a positive predictive value (PPV) of 20%. Selective reaction monitoring (SRM) was used to verify and validate panels of biomarkers in 2 independent sample sets from a prospective, international cohort of nulliparous women ( www.scopestudy. net ). In the preeclampsia prediction panels developed, insulinlike growth factor acid labile subunit (IGFALS), a novel preeclampsia biomarker, carries the most predictive weight.
Methods

Participants and Specimens
Local ethical committee approval was granted, and written informed consent was obtained from all participants.
Biomarker Discovery
Healthy, normotensive, nulliparous, and multiparous women (n=222) were recruited at Ninewells Hospital, Dundee, UK, after assessment of uterine artery Doppler waveform at a routine clinical visit, and an EDTA plasma was obtained at 22 and 26 weeks of gestation. 11 Pregnancy outcome data were available in all women, of whom 26 women (12%) developed preeclampsia defi ned using standard criteria. 12 Ten women with preeclampsia were matched for parity, ethnicity, and gestation at sampling to women with uncomplicated pregnancies (n=9).
Biomarker Verifi cation and Validation
Women who were recruited into the SCOPE (SCreening fOr Pregnancy Endpoints) study, a prospective screening study of lowrisk nulliparous women recruited in Australia, New Zealand, United Kingdom, and Ireland between November 2004 and July 2011 (ACTRN12607000551493), participated in this study. 2 A research midwife interviewed participants at 14 to 16 weeks ' and 19 to 21 weeks ' gestation, and pregnancy outcomes were prospectively tracked. At the time of interview, data were entered on the Internetaccessed central database (MedSciNet). Two consecutive manual blood pressure measurements were recorded. Blood samples were collected on EDTA at 14 to 16 and 19 to 21 weeks, and plasma was stored at − 80 ° C within 4 hours of collection.
Training Set
One hundred women who developed preeclampsia and 200 controls were randomly selected from the 3182 women recruited in Australia and New Zealand. Controls were selected 2:1 from those who did not have preeclampsia at the same center and included women with uncomplicated pregnancies and those with complications, such as small for gestational age, preterm birth, gestational hypertension, and gestational diabetes mellitus. Preeclampsia was defi ned as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg, or both, on ≥ 2 occasions 4 hours apart after 20 weeks ' gestation but before the onset of labor, or postpartum, with either proteinuria (24-hour urinary protein ≥ 300 mg or spot urine protein:creatinine ratio ≥ 30 mg/mmol creatinine or urine dipstick protein ≥ ++) or any multisystem complication of preeclampsia. 
Validation Set
Fifty cases of preeclampsia and 5:1 controls (no preeclampsia), stratifi ed by center, were randomly selected from women recruited to the European centers (London, Manchester, Leeds, UK, and Cork, Ireland; n=2423).
Mass Spectrometry Methods
N-Terminomics Discovery Platform
An N-terminomics platform, described in Mebazaa et al, 9 was used to identify candidate biomarkers in the 22-and 26-week discovery samples. In brief, N-terminomics COFRADIC (COmbined FRActional DIagonal Chromatography) 13 , 14 for complexity reduction and spotting on MALDI (matrix-assisted laser desorption/ionization) targets was used. Experimental details are provided in the online-only Data Supplement.
Quantifi cation of Candidate Biomarkers
The candidate proteins were quantifi ed in the training sample set with targeted mass spectrometry assays based on an SRM peptide quantifi cation method, 15 using custom-built assays. In brief, plasma samples were depleted of albumin and IgG, denatured and spiked with a mixture of isotopically labeled peptides serving as internal reference. After tryptic digestion, and peptide separations, quantitative data were obtained with a triple quadrupole mass spectrometry (MS) instrument. The readout of an assay in each sample was the ratio of the analyte signal area (endogenous peptide) over the common internal standard signal area. Comparison of ratios between different samples represents the relative quantifi cation of the protein. Detailed MS methods are described in the online-only Data Supplement.
The sample order was randomized before every analytic step, and laboratory personnel were blinded to the pregnancy outcome related to each sample. Technical variation was estimated by preparing and measuring in duplicate 10% of the samples in a randomized order.
PlGF was measured in all samples using DELFIA time resolve fl uorescence technology (PerkinElmer, Turku, Finland). Interassay coeffi cients of variation were 3% at 16.8 pg/mL and 8% at 852 pg/mL. In the validation samples, only IGFALS was also measured, in duplicate, by ELISA (Mediagnost, Reutlingen, Germany); samples were randomized and blinded to the Mediagnost laboratory. Coeffi cients of variation (CVs) were < 8% for all 5 reference samples.
Biomarker Panel Development
The size of the training set was chosen to achieve an accuracy for the sensitivity of ± 10% with a confi dence level of 95% for the minimum accepted performance (50% detection rate [sensitivity] at a PPV of 20%). The minimum total number of samples required to achieve this performance was 288.
R and bioconductor were used to perform all statistical analyses. 16 The characteristics of the preeclampsia group and controls were compared using Student t test, Wilcoxon rank sum test, and χ ² test. Logistic regression was used to develop multivariable models. The clinical parameters (maternal age and mean arterial pressure [MAP] ; no missing values) obtained at 20 weeks ' , protein assays (log transformed) with < 20% missing values, and a ≤ 25% CV were used for the multivariable analysis. The modeling aimed to discover all marker combinations predictive of preeclampsia using a maximum of 6 covariates to limit the risk of overfi tting the data. For each combination, a logistic regression model was fi tted on the participants with complete data; observations with outlying values were discarded. A conservative stepwise approach was used to select the models. First, the statistical signifi cance of all coeffi cients was estimated using the Wald test. A model was ignored when the Wald test for one of the coeffi cients associated with a covariate was P > 0.05. For the retained models, the discriminatory power was then estimated using the area under receiver-operator curve (AUC). Models with an AUC below 0.70 were ignored (this AUC corresponds to the AUC of the best univariate predictor; IGFALS). Finally, the sensitivity at 20% PPV was computed for the remaining models, and those with a sensitivity of ≥ 50%, the preset threshold, were retained for external validation.
Biomarker Panel Validation
The selected models were evaluated in the European samples (validation set). The performance was computed in the validation set using the models developed in the training set without any refi tting.
Healthy, normotensive, nulliparous, and multiparous women (n=222) were recruited at Ninewells Hospital, Dundee, UK, after assessment of uterine artery Doppler waveform at a routine clinical visit, and an EDTA plasma was obtained at 22 and 26 weeks of gestation.
11 Pregnancy outcome data were available in all women, of whom 26 women (12%) developed preeclampsia defi ned using standard criteria. 12 Ten women with preeclampsia were matched for parity, ethnicity, and gestation at sampling to women with uncomplicated pregnancies (n=9).
Biomarker Verifi cation and Validation
Women who were recruited into the SCOPE (SCreening fOr Pregnancy Endpoints) study, a prospective screening study of lowrisk nulliparous women recruited in Australia, New Zealand, United Kingdom, and Ireland between November 2004 and July 2011 (ACTRN12607000551493), participated in this study. 2 A research PlGF was measured in all samples using DELFIA orescence technology (PerkinElmer, Turku, Finland). Interassay coeffi cients of variation were 3% at 16.8 pg/mL and 8% at 852 pg/mL. In the validation samples, only IGFALS was also measured, in duplicate, by ELISA (Mediagnost, Reutlingen, Germany); samples were randomized and blinded to the Mediagnost laboratory. Coeffi cients of variation (CVs) were < 8% for all 5 reference samples.
Biomarker Panel Development
R and bioconductor were used to perform all statistical analyses.
by guest on April 2, 2013 http://hyper.ahajournals.org/ Downloaded from Models were considered externally validated if the sensitivity was ≥ 50% at 20% PPV ( Figure S3B in the online-only Data Supplement). Given the validation set comprised 50 cases and 250 controls, the accuracy of the sensitivity observed is expected to be ± 14% for the target performance of 50% sensitivity at 20% PPV. The possibility of a validated model occurring by chance was also assessed (see the online-only Data Supplement).
Results
An overview of the steps taken to develop, verify, and validate the prediction models is outlined in Figure 1 . The participants from the SCOPE study included in the training and validation data sets for biomarker verifi cation and validation, respectively, are shown in Figure S1 .
Biomarker Discovery
An N-terminomics platform was used to compare the plasma proteomes of women destined to develop preeclampsia (n=10) with women who had uncomplicated pregnancies (n=9) at 22-and 26-week gestation (Table S1 ). From this discovery experiment, 64 proteins were selected for verifi cation (Table S2) . Previously reported markers for preeclampsia, such as soluble endoglin (sEng), disintegrin, and metalloproteinase domaincontaining protein 12 (ADAM12) were identifi ed. In addition to these 64 proteins, 9 proteins previously identifi ed in a cardiovascular biomarker study 9 with biology relevant to preeclampsia (Table S2 ) and 3 proteins (PlGF, soluble fms-like tyrosine kinase-1, and placental protein 13) with a recognized association with preeclampsia were also taken forward to the verifi cation experiments.
Biomarker Verifi cation and Model Development
The characteristics of participants in the training and validation sets are shown in Table 1 . SRM assays were successfully developed for 51 proteins from the list of candidate biomarkers. SRM data with a CV ≤ 25% and ≤ 20% missing values were obtained for 24 different proteins (Table S2 ).
Univariate analysis revealed that IGFALS was signifi cantly elevated in 19 to 21-week plasma from women who later developed preeclampsia compared with controls (Table S3 ; Figure  S2 ). Furthermore, IGFALS was increased before both preterm ( < 37 weeks; n=30) and term preeclampsia (n=70). IGFALS had the highest performance as a single marker with 48% (95% confi dence interval [CI], 37% to 59%) sensitivity at 80% specifi city (Table S4) . PlGF, sEng, ADAM12, and 20-week MAP also signifi cantly discriminated women destined to develop preterm preeclampsia from control pregnancies ( P < 0.001; Figure S2 ).
Development of Models in Training Set
Forty-four models had a prediction performance higher than the predefi ned cutoff (sensitivity ≥ 50% at 20% PPV; Figure  S3A ). There was signifi cant overlap of protein biomarkers in these prediction models, with a small number of biomarkers (PlGF, IGFALS, melanoma cell adhesion molecule [MCAM] , sEng, ADAM12, serine peptidase inhibitor Kunitz type 1 [SPINT1]) appearing in the majority of algorithms.
Validation of Prediction Models
Of the 44 models, 8 reached the target performance of 50% sensitivity at 20% PPV for a 5% prevalence in the validation set ( Figure S3B ). These validated models included combinations of the proteins IGFALS, sEng, ADAM12, SPINT1, MCAM, selenoprotein P, multimerin-2, extracellular matrix protein 1, microtubule-associated protein RP/EB family member 1 or 3, fructose-bisphosphate aldolase A, PlGF, and blood pressure (MAP), Table 2 . The likelihood of validating 1 model by chance was computed to be < 1%.
The 8 validated models all showed very similar performance for overall preeclampsia prediction (Tables S5 and S6 ). With the exception of 1 model, these models combine IGFALS and sEng and a selection of 3 or 4 markers out of SPINT1, PlGF, MCAM, selenoprotein P, and MAP. The model that combines the 6 most frequently occurring covariates was selected as an tion to these 64 proteins, 9 proteins previously identifi ed in a cardiovascular biomarker study 9 with biology relevant to preeclampsia (Table S2 ) and 3 proteins (PlGF, soluble fms-like tyrosine kinase-1, and placental protein 13) with a recognized association with preeclampsia were also taken forward to the verifi cation experiments.
Biomarker Verifi cation and Model Development
( Figure S3B ). These validated models included combinations of the proteins IGFALS, sEng, ADAM12, SPINT1, MCAM, selenoprotein P, multimerin-2, extracellular matrix protein 1, microtubule-associated protein RP/EB family member 1 or 3, fructose-bisphosphate aldolase A, PlGF, and blood pressure (MAP), Table 2 . The likelihood of validating 1 model by chance was computed to be < 1%.
The 8 validated models all showed very similar performance for overall preeclampsia prediction (Tables S5 and S6 ). With the exception of 1 model, these models combine IGFALS and sEng and a selection of 3 or 4 markers out of SPINT1, PlGF, MCAM, selenoprotein P, and MAP. The model that combines the 6 most frequently occurring covariates was selected as an example ( Figure 2 ). Using the model, a risk index (relative risk to develop preeclampsia) was computed for each patient. A risk index cutoff corresponding to 20% PPV was computed on the training set. The cutoff corresponds to a detection rate (sensitivity) of 54% (95% CI, 37% to 66%) in the training set and 50% (95% CI, 36% to 68%) in the validation set. Preterm preeclampsia occurred in 30 women in the training and 12 women in the validation sets. Using the model for all preeclampsia and the same risk index cutoff, the detection of preterm preeclampsia was 72% (95% CI, 48% to 88%) in the training set and 80% (95% CI, 50% to 100%) in the validation set ( Figure 2 ; Tables S5 and S6) . Application of this model to a theoretical population of 1000 women would classify 125 women as being high risk of developing preeclampsia. Twenty percent of this high-risk group would later develop preeclampsia, and 10 of the 13 women who would develop preterm preeclampsia would be detected. In the test negative group, 2.9% would develop preeclampsia with 0.29% having preterm disease compared with an unstratifi ed nulliparous population where 1.2% of pregnancies would develop preterm preeclampsia.
The incremental value of the novel biomarkers over the known markers was investigated by calculating the performances of any combination of sENG, PlGF, ADAM12, and MAP: within the training data set. The best model (combination of PLGF, ADAM12, and MAP) had a sensitivity of 30% at 20% PPV; data not shown). A comparison with the performance of the National Institute for Health and Clinical Excellence (NICE) risk factor model 17 and the best combination of markers in a comparable population 4 are presented in Table 3 .
Substitution of SRM Data With ELISA Data for IGFALS
There was good correlation between the SRM and ELISA measurements of IGFALS ( r =0.63; P < 0.001; Spearman rank correlation; Figure S4 ). Substitution of IGFALS SRM data with ELISA measurements in the example model did not change its performance. The risk index of the model using the SRM readouts also correlated well with the risk index using the ELISA measurements ( r =0.89; P < 0.001; Spearman rank correlation; Figure S4 ), resulting in a detection rate of 59% (95% CI, 41% to 73%) at 20% PPV.
Discussion
In this study, we identifi ed a number of novel biomarkers associated with the later development of preeclampsia in low-risk nulliparous women. These biomarkers, together with known biomarkers, were then used to develop predictive models that met à priori criteria (detection of ≥ 50% of preeclampsia cases with a PPV of 20%, given a disease prevalence of 5%). During the development of predictive models, 4 of these novel biomarkers, IGFALS, MCAM, selenoprotein P, and SPINT1, were highly recurrent. In combination with known biomarkers (PlGF and sEng) and MAP, these markers achieved predictive performances with the potential to identify a subgroup of healthy nulliparous women who could receive specialist prenatal care. Overall preeclampsia detection rates ranged from 50% to 56% in the training set and 50% to 54% on (22) 16 (8) 17 (34) 33 (13) Gestational hypertension … 13 (7) … … Gestational diabetes mellitus 7 (7) 6 (3) 1 (2) 2 (1) Results are expressed as mean (SD), median (interquartile range), or n (%). * Urine dipstick ≥ 2+ or 24-h urine protein excretion ≥ 300 mg or spot urine protein:creatinine ratio ≥ 30 mg/mmol. † P < 0.05; ‡ P < 0.001 cases vs controls. Figure 2 ). Using the model, a risk index (relative risk to develop preeclampsia) was computed for each patient. A risk index cutoff corresponding to 20% PPV was computed on the training set. The cutoff corresponds to a detection rate (sensitivity) of 54% (95% CI, 37% to 66%) in the training (NICE) risk factor model 17 and the best combination of markers in a comparable population 4 are presented in
Substitution of SRM Data With ELISA Data for IGFALS
There was good correlation between the SRM and ELISA measurements of IGFALS ( =0.63; P < 0.001; Spearman rank Small for gestational age 22 (22) 16 (8) 17 (34) Gestational hypertension … 13 (7) … Gestational diabetes mellitus 7 (7) 6 (3) 1 (2) Results are expressed as mean (SD), median (interquartile range), or n (%). 2+ or 24-h urine protein excretion ≥ 300 mg or spot urine protein:creatinine ratio ≥ 30 mg/mmol. < 0.001 cases vs controls.
external validation, with ≈ 3 quarters of preterm preeclampsia cases detected.
Fundamental to the identifi cation of novel algorithms to predict preeclampsia was the application of the discoveryverifi cation-validation proteomics pipeline. Our discovery proteomic approach capitalized on sensitivity gains achievable by using N-terminomics 13 to identify novel biomarkers associated with later preeclampsia. The samples used for the biomarker discovery experiments were taken from a cohort of samples completely independent to the SCOPE cohort, 11 at different gestational ages and with different risk factors for the development of preeclampsia. Although it is probable that a modifi ed list of proteins would have been identifi ed had the discovery experiment been performed in a subset of the SCOPE cohort, independent verifi cation of several biomarkers across these 2 independent populations adds further credibility to the fi ndings. Our quantitative MS assays enabled simultaneous determination of the concentration of 20+ lower abundant plasma proteins (many without established immunoassays) in 25 µ L of plasma. Our study highlights the capability of LC-SRM assays to bridge the gap between discovery experiments (many candidates, large number of false positives) and clinical validation studies where fewer markers are studied in 100s of women. The importance of verifi cation and validation of biomarkers in clinical proteomic studies cannot be overstated. Even with the use of highly sensitive unbiased MS techniques, there is a high attrition of biomarkers when measured in a larger independent sample set. Furthermore, in a heterogeneous clinical condition, the univariate performance of individual proteins is superseded by the performance of a combination of proteins within predictive models. Predictive models will always have the highest accuracy in the population in which they were created, even where steps have been taken to minimize overfi tting. External validation in an independent sample set provides a much more robust estimate of the predictive performance if translated into clinical settings.
The algorithms devised in this study were selected to enrich, within a population of low-risk nulliparous women where risk factor screening is not adequate, 2 a subgroup with a disease prevalence equivalent to current high-risk obstetric clinics, 10 that is, a PPV of 20%. Such a screening test would allow stratifi cation of prenatal care, with nulliparous women who screen positive receiving increased antenatal surveillance along with intervention to prevent preeclampsia. 18 In comparison with reported multimarker combinations, 4 and the NICE risk factor assessment tool, the models devised in this study perform favorably (Table 3 ) with better detection rates and lower numbers of false positives in healthy nulliparous women.
Comparison with other algorithms is problematic as general populations, comprising high-risk and low-risk women, have been studied. 3 There are several additional clinical variables, including body mass index, 2 which could improve the performance of the biomarkers measured in this study. In future validation studies, which would require the measurement of far Fundamental to the identifi cation of novel algorithms to predict preeclampsia was the application of the discoverymeasured in a larger independent sample set. Furthermore, in a heterogeneous clinical condition, the univariate performance of individual proteins is superseded by the performance of a combination of proteins within predictive models. Predictive fewer biomarkers, it may be appropriate to include body mass index and other clinical variables within the model. IGFALS, which was increased in the plasma of women who developed preeclampsia, is part of the ternary insulin-like growth factor complex. It is known to complex with IGFBP3 and IGFBP5 (insulin-like growth factor binding protein), proteins that control the bioavailability of IGFs, which are crucial for placental development and growth. The acid labile subunit prevents the transport of the insulin-like growth factor complex across the endothelium into tissues confi ning them to the circulation. High levels of placental IGFALS mRNA have previously been reported in small for gestational age babies 19 and increased serum levels in women with established severe preeclampsia (n=8). 20 The other novel biomarkers, MCAM and SPINT1, decreased in women destined to develop preeclampsia consistently improved performance within the multivariable models. MCAM is an endothelial adhesion molecule, important in maintenance of the endothelial monolayer. It is highly expressed by placental trophoblasts with decreased expression in placentas from women with preeclampsia.
21
SPINT1 is a cell surface -binding protein of hepatocyte growth factor activator, which regulates hepatocyte growth factor activity. Hepatocyte growth factor contributes to the repair of injured tissues, is abundantly expressed by villous cytotrophoblasts, 22 and thought to be essential for placental development. 23 Although this study benefi ts from rigorous protocols related to sample and data collection across 6 centers in 4 countries, it has some limitations. The study size is modest and certain ethnic groups are under-represented. Samples taken at 20-week gestation were used because of their temporal proximity to samples used in the discovery experiment. Although this time point has the advantage of coinciding with a standard antenatal care milestone (fetal anomaly scan), this must be balanced against the greater potential benefi t of prophylactic aspirin, if Number of cases of preterm preeclampsia detected 10 4
Number of false-positive screening tests 100 108 186
Ratio false positives to true positives 4:1 9:1 7:1 * As applied to the SCOPE cohort.
3 † Numbers extracted from published data as applied to a low-risk nulliparous population.
fewer biomarkers, it may be appropriate to include body mass index and other clinical variables within the model. IGFALS, which was increased in the plasma of women who developed preeclampsia, is part of the ternary insulin-like growth factor complex. It is known to complex with IGFBP3 and IGFBP5 (insulin-like growth factor binding protein), proteins that control the bioavailability of IGFs, which are crucial for placental development and growth. The acid labile subunit important in maintenance of the endothelial monolayer. It is highly expressed by placental trophoblasts with decreased expression in placentas from women with preeclampsia. SPINT1 is a cell surface -binding protein of hepatocyte growth factor activator, which regulates hepatocyte growth factor activity. Hepatocyte growth factor contributes to the repair of injured tissues, is abundantly expressed by villous cytotrophoblasts, 22 and thought to be essential for placental development.
by guest on April 2, 2013 http://hyper.ahajournals.org/ Downloaded from commenced before 20 weeks. 18 The benefi t of aspirin may well be retained in high-risk nulliparous women if commenced at 20 weeks, but this would need to be assessed in a prospective trial.
Multivariable panels will always be diffi cult to establish in the context of a low-prevalence disease; the study design used here attempts to limit the chance of over fi tting and selection of false positives variables by limiting the number of variables available to the models and using 2 independent sample sets. Validation of only 8 of the 44 models in the test set indicates that over fi tting is likely in the training data. The validated models are expected to be generalizable. Given the consistency of the proteins retained in all validated models, it is likely that the combination of proteins identifi ed in this study is robust.
The proteins in this study have been quantifi ed using mass spectrometric methods, which are not currently used in the clinical setting. Commercial ELISA kits are available for several of the markers (PlGF, ADAM12, sEng), and importantly, measurement of IGFALS using ELISA measurements produced equivalent predictive performance to the SRM quantifi cation. Before any clinical application of the biomarker combinations identifi ed in this study, further prospective studies will need to be undertaken with the biomarkers measured on a platform used in clinical laboratories (eg, ELISA) and the predictive algorithms evaluated in an adequately sized cohort of nulliparous women.
Perspectives
By defi nition, low-risk nulliparous women do not have a history of signifi cant medical disease or previous hypertensive disease in pregnancy, and therefore conventional clinical risk factor models do not perform well in this group. In current high-risk clinic settings (eg, previous preeclampsia, chronic medical disease), the rate of preeclampsia is ≈20%, and therefore, we set out to develop a model that had a PPV of ≥ 20%. This level of risk would justify referral of women with a positive test for specialist care with a manageable number of false positives. Novel biomarkers relevant to the prediction of preeclampsia were confi rmed in 2 independent sample sets in this study, and IGFALS has emerged as a novel marker, predictive of term and preterm preeclampsia. In the future, it is likely that biochemical markers will be combined with a modest number of easily recordable clinical risk markers to improve the prediction of preeclampsia in this low-risk population. 
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What Is New?
• This study identifi ed insulin-like growth factor acid labile subunit, selenoprotein, serine peptidase inhibitor Kunitz type 1, and melanoma cell adhesion molecule as novel biomarkers for preeclampsia.
• The combination of insulin-like growth factor acid labile subunit with blood pressure, along with other biomarkers, has the potential to be part of a clinically relevant predictive test for preeclampsia.
What Is Relevant?
• Application of this test could improve our ability to identify a subgroup of women at signifi cant risk of preeclampsia among nulliparous women. Women with a positive test would have a 1 in 5 chance of developing preeclampsia, which equates to the risk in current high-risk obstetric clinics.
• The algorithm developed in this study could detect up to 50% of all preeclampsia and 80% of preterm preeclampsia cases arising in a low-risk nulliparous population. Detection of the majority preterm preeclampsia cases would allow intervention strategies, such as lowdose aspirin.
• A negative test does not adequately risk stratify women at very low risk of preeclampsia to modify management.
Summary
This study has identifi ed insulin-like growth factor acid labile subunit as a novel candidate biomarker for preeclampsia; predictive models containing this marker have been validated in 2 independent sample sets.
Novelty and Signifi cance
adhesion molecule as novel biomarkers for preeclampsia.
The combination of insulin-like growth factor acid labile subunit with blood pressure, along with other biomarkers, has the potential to be part of a clinically relevant predictive test for preeclampsia.
What Is Relevant?
Application of this test could improve our ability to identify a subgroup of women at signifi cant risk of preeclampsia among nulliparous women. Women with a positive test would have a 1 in 5 chance of developing preeclampsia, which equates to the risk in current high-risk obstetric clinics. preeclampsia cases would allow intervention strategies, such as lowdose aspirin.
Summary
3 linear gradient of 1%B/min at a constant flow rate of 80µL/min. For the primary separation step, twelve 4-minute LC fractions were collected. The fractions were repeatedly (3x) dried under vacuum and dissolved in 50mM boric acid (Merck) buffer pH 9.5; the final residue was reconstituted in 50 µL 50mM boric acid pH 9.5. Then, N-terminal labeling was achieved by adding 4 times 10 µL of 10mM 2,4,6-trinitrobenzenesulfonic acid (TNBS) (Fluka) in 50mM borate buffer pH 9.5 to each of the 12 fractions with 30 min intervals. Prior re-injection on the LC-system the 12 fractions were acidified to pH 4 (10% HOAc) and supplemented with 10mM sodium acetate in 96:4 (v/v) H 2 O:ACN to 510 µL. All 12 reacted fractions were then separated under identical chromatographic conditions as used during the primary separation step. For each of the 12 secondary chromatography's the original 4 minute collection window was further distributed in sixteen 15s fractions, with the collection recipients being the injection vials for the below nano-LC separations. All uneven secondary separations (1,3,5,7,9,11) were collected in one set of sixteen vials and all even secondary separations (2, 4, 6, 8, 10, 12) in another set of sixteen vials totaling in thirty-two different pooled collections. The 32 peptide pools (COFRADIC fractions) were then dried under vacuum and stored at -20°C till further processing by nano-LC.
Peptide separation:
Each of the 32 COFRADIC fractions was reconstituted in 44 µL of 0.1% formic acid (FA, ULC-MS grade; H 2 O; ULC-MS grade) (Biosolve) and further separated using an Ultimate-3000 nano-LC system (Dionex, Amsterdam, The Netherlands). The LC unit was directly coupled to a Probot system (Dionex) equipped for direct spotting on Opti-TOF LC/MALDI inserts (Applied Biosystems). The mobile phases were 0.1% FA (ULC-MS grade) (solvent A) and 0.1% formic acid in 20:80 (v/v) H 2 O:ACN (ULC-MS grade) (solvent B). 20µL sample injections were made on a column-switching set up combining a 300 µm x 5 mm C18 PepMap pre-column and a 75µm x 15cm C18 PepMap nano-column (Acclaim PepMap100; 3µm particle size, 100Å pore size) (Dionex). Peptides trapped on the pre-column were back-flushed to the analytical column and separated using a 57 minute gradient from 4% to 55% solvent B at a flow rate of 300nL/min. The column efflux was mixed inline (T-piece) in 1:4 ratio with a matrix solution, consisting of 4mg/mL alpha-cyano-4-hydroxy-cinnamic acid (LaserBio Labs, Cedex, France) in 0.1% trifluoroacetic acid in 30:70 (v/v) H 2 O:ACN (ULC-MS grade). 65 minutes of the chromatography was spotted with a spotting interval of 15 seconds, i.e., 260 spots per nano-LC run. Per original plasma sample this culminated in 32 x 260 spots or 8320 spots. To the matrix solution also an internal standard of 5 peptides (PepMix 4, LaserBio Labs) was added for later mass calibration in the mass spectrometer.
Feature selection using MALDI:
MS spectra were acquired with MALDI-TOF/TOF instrumentation (4800 series, Applied Biosystems, Darmstadt, Germany) operated in the MS reflector positive ion mode, using the 4000 Series Explorer TM software. For each MS spectrum 1,000 laser shots were fired (25 sub-spectra; 40 shots per subspectrum). Focus mass was set at 1,800Da and peptides in a mass range from 500 to 4,000 were detected. Internal calibration was based on the five standard peptides (pepMix4).
The resulting sets of LC x LC-MS signals were deconvoluted to obtain for each detectable peptide a relative quantitation across all samples: an in-house developed software suite performs peak 4 deisotoping, accurate 16 O/ 18 O ratio determination and clustering of all mass spectrometric peaks belonging to the same peptide together (Pronota, Zwijnaarde, Belgium). The resulting features take into account the three dimensions of the pipeline: COFRADIC fraction (from 1 to 32), retention time in the Nano-LC run and mass-to-charge ratio (m/z). The so-obtained unambiguously definition of peptides permitted their identification at a later stage by targeted tandem MS analysis (see below).
Statistical analysis:
Within the experimental set-up, both the 22 weeks and the 26 weeks plasma samples of the 10 preeclampsia destined women were analysed (10+10; paired samples), whereas the 9 controls were split over the 2 gestation time points (5+5; all but 1 unpaired samples). The final data analysis was performed on 28 samples following unaccounted for contaminations in 2 samples (1: preeclampsia 22 weeks; 2: Control 26 weeks) preventing their proper alignment with the other samples.
Upon establishment of the relative concentration using the ratio unlabeled vs. labeled signal of all features (peptides) over all samples, a feature expression set was compiled for further analysis. In addition comprehensive inclusion lists were generated from 2 individual samples (a 22 wks and a 26 wks case sample; different donors) to enable mapping of non-differential features on the data matrix.
Biomarker candidate identification:
5 For the acquisition of MS/MS spectra the MALDI-TOF/TOF instrument was operated in the MS reflector positive ion mode. For each MS/MS spectrum 3,600 (60 shots for each of the 60 sub-spectra) laser shots were fired. Timed ion selector window was set at 450 full width half maximum. No internal calibration was done. Precursor masses were selected according to the above inclusion list. Generation of mgf files was done without any filtering based on S/N or number of signals. Masses below 60Da and above the precursor mass minus 20Da were excluded. Protein identification was performed using an analysis pipeline compliant with the COFRADIC principle. 3 For linking peptides to proteins a peptide representative approach was followed whereby a protein is reported when at least one valid, peptide identification was available. Spectra that were not identified with Mascot or were identified with low scores were evaluated with other search engines such as ProteinPilotTM 2.0 (Applied Biosystems, Darmstadt, Germany) and PEAKS Studio 4.5 (Bioinformatics Solutions Inc., Waterloo, Canada). In some cases, spectra of interest were evaluated manually using SPIDER (part of PEAKS Studio 4.5).
When multiple peptide identifications accounted for a single protein, the protein was discarded when the expression profiles of the different peptides diverged. From the resulting list of proteins with eventual biomarker potential, abundant plasma proteins like complement and coagulation factors were further eliminated. The 64 retained candidate biomarker proteins are listed in Table S2 .
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Quantification of Candidate Biomarkers
Assay development:
For each of the proteins in the list of biomarker candidates as derived from the N-terminomics effort, proteotypic tryptic peptides were selected. Criteria for selection include size, mass, hydrophobicity, absence of amino acids and amino acid combinations (C, M, W, RP, KP), presence of amino acids (P), uniqueness in the human proteome, absence of potential sites for posttranslational modification, etc. as described in Lange et al. 4 Isotopically labeled variants of the selected peptides (crude FasTrack peptides) (Thermo Biopolymers, Thermo Fisher Scientific, Ulm, Germany) were used to determine optimal experimental conditions (fractionation, nano-LC, MS and MS/MS).
SRM analyses:
Plasma samples (25µL) were depleted using the ProteoPrep immunaffinity albumin and IgG depletion kit (Sigma) as described by the manufacturer, but with 20mM ammonium bicarbonate buffer pH 8.0 as binding buffer. The non-bound proteins were denatured by heat at 99°C for 15 min followed by immediate cooling on ice. At this stage, a spike mixture of isotopically labeled peptides (heavy AQUA peptide, Thermo Scientific), 2000 fmol each, was added as internal reference. Next, proteins were digestion with sequencing grade modified Trypsin (Promega) for 16h at 37°C ; digestion was halted by immediate storing of the samples at -80°C (till further processing). Peptides were separated based on different physicochemical parameters before quantification using a triple quadrupole MS instrument (Vantage TSQ; Thermo Scientific) equipped with a NanoSpray ion source (Thermo Scientific). The mass spectrometer was on-line coupled to an Ultimate-3000 nano-LC system (Dionex). The mobile phases were 0.1% FA (ULC-MS grade), solvent A; and 0.1% formic acid in 20:80 (v/v) H 2 O:ACN (ULC-MS grade), solvent B. Peptides were separated on a C18 nano-column (Acclaim PepMap100 -75µm x 25cm; 3um particle size, 100Å pore size) (Dionex) using a 30 minute gradient from 4% to 55% solvent B at of 200nl/min. The mass spectrometer was operated in ESI+ mode, with application of a spray voltage of 1600V and a capillary temperature of 150°C. Both Q1 and Q3 resolution were set at 0.7 Da (FWHM). Different peptides/transitions were monitored within one run using multiplexed scheduled SRM: transitions were measured for a time period starting 3 minutes before and ending 3 minutes after the determined peptide retention times, each peak needed at least 10 datapoints.
The SRM data were analysed using LCQUAN (Thermofisher Scientific). The readout of the assay in each sample was the ratio of the analyte signal area (endogenous peptide) and the common internal standard signal area (AQUA peptide). Comparison of ratios between different samples represents the relative abundance of each protein.
Technical variation was estimated by preparing and measuring, in duplicate, 10% of the samples in a randomized order throughout the analytical process. Only assays with interassay coefficients of variation (CV) ≤ 25% and not more than 20% missing data in the 300 samples of the "Training Set" were 7 retained for biomarker panel development. From the 300 plasma samples from the Training Set 2 samples were lost during preparation, i.e, 1 case and 1 control pregnancy.
For 51/64 proteins satisfactory SRM assays were available (Table S2) ; from these 51 proteins, 24 protein assays met the predefined QC criterion of ≤25% CV and ≤20% missing data. For these 24 protein assays %CVs were ≤10% for 3 proteins, ≤15% for 12 proteins and 4 protein assays showed a CV ≥20%; all protein assays but one had less than 5% missing values (Table S1 ).
Computation of type 1 error
The training and validation procedure was repeated 1500 times on randomised datasets to empirically determine the significance level of the observations. At each iteration, the outcome labels together with the known pre-eclampsia markers (PlGF, sENG, ADAM12) and risk factors (age, Bp) were randomly permutated. The relationship between these parameters was kept in order to preserve the diagnostic performance of the known markers and risk factors. In only four of the 1500 iterations could we find models that complied with the success criteria. In three of these iterations, one valid model was found and in a fourth three valid models were found. This indicates that the likelihood to observe at least one valid model by chance is lower than 1% (type I error). Table S5 . Eight models that have a performance equal or higher than the target both in the training and test sets -formulas model covariates Covariates (n) formula Figure S1 . Flowchart describing the selection of subjects in the training and validation sample sets. 
